CoChat

Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide

Open access
Flint, Anne, Nazzal, Khalil, Jagielski, Pawel, Hindsberger, Charlotte, Zdravkovic, Milan · 2010 · British Journal of Clinical Pharmacology
Cited by 80

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Liraglutide is a novel human GLP‐1 analogue approved for treatment of type 2 diabetes mellitus. Since there is a high prevalence of co‐morbid hepatic impairment in this population it is of clinical importance to establish whether the pharmacokinetics of liraglutide are affected by hepatic impairment. WHAT THIS STUDY ADDS • This study shows that hepatic impairment does not increase liraglutide exposure. Rather, total exposure tends to decrease with increasing degree of hepatic impairment. AIMS: To compare the pharmacokinetics (PK) of a single‐dose of liraglutide in subjects with hepatic impairment. METHODS: This parallel group, open label trial involved four groups of six subjects with healthy, mild, moderate and severe hepatic impairment, respectively. Each subject received 0.75 mg of liraglutide (s.c., thigh), and blood samples were taken over 72 h for PK assessment. Standard laboratory and safety data were collected. The primary endpoint was area under the plasma liraglutide concentration–time curve from time zero to infinity (AUC(0,∞)). RESULTS: Exposure to liraglutide was not increased by hepatic impairment. On the contrary, mean AUC(0,∞) was highest for healthy subjects and lowest for subjects with severe hepatic impairment (severe/healthy: 0.56, with 90% CI 0.39, 0.81) and equivalence in this parameter across groups was not demonstrated. Cmax also tended to decrease with hepatic impairment (severe/healthy: 0.71, with 90% CI 0.52, 0.97), but tmax was similar across groups (11.3–13.2 h). There were no serious adverse events, hypoglycaemic episodes or clinically significant changes in laboratory parameters and liraglutide was considered well tolerated. CONCLUSIONS: This study indicated no safety concerns regarding use of liraglutide in patients with hepatic impairment. Exposure to liraglutide was not increased by impaired liver function; rather, the results suggest a decreased exposure with increasing degree of hepatic impairment. However, data are not conclusive to suggest a dose increase of liraglutide. Thus, the results indicate that patients with type 2 diabetes mellitus and hepatic impairment can use standard treatment regimens of liraglutide. There is, however, currently limited clinical experience with liraglutide in patients with hepatic impairment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2010.03762.x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 80

Metadata

Authors
Flint, A., Nazzal, K., Jagielski, P., Hindsberger, C., & Zdravkovic, M.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2010-11-11
Volume
70
Issue
6
Pages
807-814
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W1485586005
Cited by
80
References
5
FWCI
4.84
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide. https://app.cochat.ai/papers/10.1111/j.1365-2125.2010.03762.x
The paper
Flint, A., Nazzal, K., Jagielski, P., Hindsberger, C., & Zdravkovic, M. (2010). Influence of hepatic impairment on pharmacokinetics of the human GLP‐1 analogue, liraglutide. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2010.03762.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.